Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PTPalatin Technologies, Inc. logo

Palatin Technologies, Inc. (PTN)

NASDAQ Capital Market · Currency in USD
$5.11 ▼ -0.40 (-7.26%)
At close: Oct 23, 4:00 PM ET. Market closed.
$5.01 ▼ -0.10 (-1.96%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$5.51
Open
$5.44
Day's Range
$4.95 – $5.89
52 Week Range
$4.92 – $31.00
Volume
126,574
Avg. Volume
54,204
Market Cap
$9.10M
Beta (5Y Monthly)
-0.07
PE Ratio (TTM)
--
EPS (TTM)
-$2.14
Earnings Date
Nov 16, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$47.50

Profile: Palatin Technologies, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
25
CEO
Carl Spana

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases.

Earnings

Next report: Mon, Nov 16, 2026
EPS estimate -$0.42 · Revenue est. $2.51M
DateEst.Actual
Sep 28, 2026-$1.20-$1.11Beat
May 13, 2026-$1.24-$0.37Beat
Feb 17, 2026-$2.35-$2.86Miss
Nov 14, 2025–$4.26
Sep 23, 2025-$9.50-$3.43Beat
May 14, 2025-$8.50-$9.00Miss

Analyst view

Consensus price target
$47.50 ▲ +829.5%
Range $47.50 – $47.50
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on PTN and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.